Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tafasitamab-combo-boosts-r-chop-frontline-dlbcl-2026a1000i14?src=rss
Author :
Publish date : 2026-05-30 12:05:00
Copyright for syndicated content belongs to the linked Source.
